NeoGenomics downgraded to Hold at Benchmark on below-peer margins

As previously reported, Benchmark downgraded NeoGenomics (NEO) to Hold from Buy and removed the firm’s prior $18 price target on the shares. The company has gross margins below its peer group average with in-line consensus sales growth for 2025, notes the analyst, who views the stock as fairly valued given these factors. Shares of NeoGenomics, which fell 20% last Friday following the “surprise announcement” that Chris Smith is stepping down from his role as CEO, are down another $2.34, or 16%, to $12.43 in Monday morning trading.